Ildong to market Shionogi’s pirfenidone in Korea

Published: 2011-07-15 06:56:00

Updated: 2011-07-15 06:56:00

Ildong Pharmaceutical said Tuesday that it entered into a licensing agreement with Shionogi & Co., Ltd. on May 30 for the sale of pirfenidone in Korea on an exclusive basis.

Following the execution of agreement, Ildong will file a New Drug Application and exclusively sell this product in Korea...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK